J Clin Endocrinol Metab 2011 Oct;96 (10): E1619-29. [IF:6.495]
Tumor expression of human growth hormone and human prolactin predict a worse survival outcome in patients with mammary or endometrial carcinoma.
Wu ZS , Yang K , Wan Y , Qian PX , Perry JK , Chiesa J , Mertani HC , Zhu T , Lobie PE .
Hefei National Laboratory for Physical Sciences at Microscale, University of Science and Technology of China, Hefei, Anhui 230027, People’s Republic of China.
合肥微尺度物质科学国家实验室，中国科学技术大学
Abstract
Evidence suggests that human GH (hGH) and human prolactin (hPRL) possess an autocrine or paracrine oncogenic role in mammary and endometrial carcinoma. However, especially for hGH, the prognostic relevance of tumor expression of these hormones is not well defined. We investigated the potential association of tumor mRNA and protein expression of hGH and hPRL with the clinicopathological features of mammary and endometrial carcinoma. The prognostic relevance of the individual or combined expression of hGH and hPRL in mammary and endometrial carcinoma was also determined. The expression of hGH and hPRL was analyzed in histopathological samples of mammary and endometrial carcinoma, and the respective normal tissues, by in situ hybridization and immunohistochemistry. Kaplan-Meier and Cox regression analysis was performed to examine the association of tumor hGH and hPRL expression with relapse-free survival and overall survival of patients. hGH expression was significantly associated with lymph node metastasis, tumor stage, human epidermal growth factor receptor-2 status, and proliferative index in mammary carcinoma and with International Federation of Gynecology and Obstetrics grade, myometrial invasion, and ovarian metastases in endometrial carcinoma. hPRL expression was associated with lymph node metastasis, tumor grade, and tumor stage in mammary carcinoma and with International Federation of Gynecology and Obstetrics stage and myometrial invasion in endometrial carcinoma. Both hGH and hPRL expression, individually and combined, are associated with worse relapse-free survival and overall survival in patients with mammary or endometrial carcinoma. Tumor expression of both hGH or hPRL in mammary or endometrial carcinoma is associated with a large and significant difference in survival outcome for patients with these tumors.
摘要
事实证明，乳腺癌和子宫内膜癌以自分泌或旁分泌方式分泌的人生长激素和人催乳素具有致肿瘤作用。然而，肿瘤表达得这些激素，特别是人生长激素，与预后的相关性还没有很好的阐明。我们研究了乳腺癌和子宫内膜癌中人生长激素和人催乳素的mRNA和蛋白的表达水平与临床病理特征的相关性，同时也研究了乳腺癌和子宫内膜癌中人生长激素和人催乳素的独立或联合表达与预后的相关性。乳腺癌和子宫内膜癌患者的组织病理样本和相应的正常组织的样本，通过原位杂交和免疫组织化学来研究生长激素和人催乳素的表达。对病人无复发生存时间和总生存时间与肿瘤人生长激素和人催乳素的表达进行了Kaplan-Meier和Cox 回归分析。人生长激素的表达和乳腺癌的淋巴结转移、肿瘤分期、人表皮生长因子受体2状态和增殖指数以及与子宫内膜癌的国际联邦妇产科学级别、子宫肌层的浸润和卵巢转移有显著相关性。人生长激素和人催乳素的独自或联合表达与乳腺癌或子宫内膜癌患者的较差的无复发生存时间和总生存时间相关。在乳腺癌和子宫内膜癌患者中，肿瘤表达人生长激素和或人催乳素得水平与这些肿瘤患者的生存结果的显著差异相关。
